[The first original Russian class-III antiarrhythmic nibentan].
The paper presents experimental and clinical findings of the new antiarrhythmic drug nibentan. The agent was found to be a class-III antiarrhythmic agent in terms of its electrophysiological effects and an inhibitor of the delayed rectifier potassium current in terms of its effects on the ionic channels of cardiomyocytes. The clinical trial of nibentan shows that the drug is highly effective (in 70-100% of cases) in patients with atrial flutter and fibrillation and in those with supraventricular tachycardia and it is less effective in suppressing ventricular premature contractions and tachycardia. The rate of arrhythmogenic effects produced by the drug was inversely related to its antiarrhythmic action. Nibentan has been approved for clinical use.
Glushkov
R G
RG
Golitsyn
S P
SP
Dorodnikova
E V
EV
Maĭkov
E B
EB
Mashkovskiĭ
M D
MD
Merkulova
I N
IN
Rozenshtraukh
L V
LV
Ruda
M Ia
MIa
Skachilova
S Ia
SIa
Chazov
E I
EI
Iuzhakov
S D
SD
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology; D001549:Benzamides / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D004562:Electrocardiography / Q000187:drug effects; D004594:Electrophysiology; D006801:Humans; D051381:Rats
D000889:Anti-Arrhythmia Agents; D001549:Benzamides; C105049:nibentan